Technical Analysis for GNHAF - Vifor Pharma AG

Grade Last Price % Change Price Change
grade B 151.2317 0.99% 1.4817
GNHAF closed up 0.99 percent on Thursday, July 25, 2019, on 5.17 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A Up
See historical GNHAF trend table...

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Narrow Range Bar Range Contraction 0.00%
Gapped Up Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Up 5 Days in a Row Strength 0.00%
Narrow Range Bar Range Contraction 0.99%
Gapped Up Strength 0.99%
Up 3 Days in a Row Strength 0.99%

Older signals for GNHAF ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Vifor Pharma AG develops, manufactures, and distributes pharmaceutical products in Switzerland, Europe, the United States, and internationally. It offers iron products, including Ferinject, Venofer, Maltofer, and Velphoro; Veltassa, a sodium-free potassium binder for the treatment of hyperkalaemia in adult patients; and Mircera, an erythropoiesis-stimulating agent for the treatment of symptomatic anemia associated with chronic kidney diseases. The company also provides infectious diseases/over-the-counter products, such as Broncho-Vaxom, an extract of various bacterial species for the treatment and prevention of recurrent respiratory infections; Uro-Vaxom, an extract of the bacterium Escherichia coli for the treatment and prevention of recurrent urinary tract infections; Dicynone for the prevention and treatment of capillary haemorrhages; Doxium for the oral treatment of diabetic retinopathy; and Aero-OM, an anti-flatulent for the oral treatment. Its development/pre-clinical products include VIT-2763, an oral ferroportin inhibitor, which is Phase I clinical trial for the treatment patients suffering from iron overload; Rayaldee for the treatment of secondary hyperparathyroidism in chronic kidney disease (CKD) and vitamin D deficiency; Biosimilar epoetin alfa the treatment of anemia associated with CKD, renal failure, and chemotherapy-induced anemia; Avacopan/CCX168, an orally administered inhibitor; CCX140, an orally administered inhibitor of the chemokine receptor; and Vadadustat, an oral investigational hypoxia-inducible factor stabiliser that is in Phase-III development for the treatment of anemia related to CKD. The company was formerly known as Galenica AG and changed its name to Vifor Pharma AG in April 2017. Vifor Pharma AG was founded in 1927 and is headquartered in St. Gallen, Switzerland.
Medicine RTT Medical Specialties Branches Of Biology Pharmaceutical Pharmaceutical Products Infectious Diseases Chemotherapy Diabetic Retinopathy Chronic Kidney Disease Anemia Chronic Kidney Diseases Organ Failure Erythropoiesis Stimulating Agent Chemotherapy Induced Anemia Iron Products Secondary Hyperparathyroidism Acetic Acids And Velphoro Development/Pre Clinical Products Galenica Including Ferinject Infectious Diseases/Over The Counter Products Iron Overload Maltofer Recurrent Respiratory Infections Recurrent Urinary Tract Infections Renal Failure Sucroferric Oxyhydroxide Symptomatic Anemia Treatment Of Secondary Hyperparathyroidism In Chronic Kidney Disease Vadadustat Velphoro Venofer Vifor Pharma Vit 2763 Vitamin D Deficiency
Is GNHAF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicator Value
52 Week High 178.4031
52 Week Low 123.9861
Average Volume 348
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 0.0
10-Day Moving Average 134.1714
Average True Range 7.9929
ADX 0.0
+DI 52.1592
-DI 47.8367
Chandelier Exit (Long, 3 ATRs ) 154.4244
Chandelier Exit (Short, 3 ATRs ) 147.9648
Upper Bollinger Band 0.0
Lower Bollinger Band 0.0
Percent B (%b) 0.0
BandWidth 0.0
MACD Line 1.0187
MACD Signal Line -0.3618
MACD Histogram 1.3805
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 151.2317
Resistance 3 (R3) 151.2317 151.2317 151.2317
Resistance 2 (R2) 151.2317 151.2317 151.2317 151.2317
Resistance 1 (R1) 151.2317 151.2317 151.2317 151.2317 151.2317
Pivot Point 151.2317 151.2317 151.2317 151.2317 151.2317
Support 1 (S1) 151.2317 151.2317 151.2317 151.2317 151.2317
Support 2 (S2) 151.2317 151.2317 151.2317 151.2317
Support 3 (S3) 151.2317 151.2317 151.2317
Support 4 (S4) 151.2317